Huyabio International, LLC

Syndax Pharmaceuticals, Inc.

Huya Bioscience International, LLC

Robert Goodenow

Mireille Gillings

Gary Elliott

Suzanne J Romano

Peter Ordentlich

Hayley Reece

Farbod Shojaei

Joseph Edward Gordon Benson

Jay Mason

Sarah Collins

Waldemar Radziszewski

Curtis Tyree

Jill M Ricono

Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Sulcardine administration for treatment of acute atrial fibrillation

Provided herein are SHP2 inhibitors for use in the reduction of solid tumors in a method of treating cancer.

SHP2 inhibitor monotherapy and uses thereof

Provided herein are combinations that include a SHP2 inhibitor and a PD-1 inhibitor and methods of treating cancer.

Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors

Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Sulcardine salts

Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.

Growing community of inventors

San Diego, CA, United States of America

Robert Goodenow